Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520958 | 0.83 | MC4R (0.49) | TSHRKMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14355839 | 0.82 | HTR6 (0.50) | TSHRKMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4529470 | 0.79 | MC4R (0.57) | TSHRKMT2AHTTMEN1MAPT | |
| SCHEMBL14356029 | 0.78 | ADRB1 (0.50) | TSHRMAPT | |
| SCHEMBL4524859 | 0.73 | NPY5R (0.52) | TSHRKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL631024 | 0.72 | AKR1C3 (0.65) | TSHRKMT2AHTTPOLBALDH1A1 | |
| SCHEMBL2857040 | 0.71 | AKR1C3 (0.64) | KMT2AHTTMEN1MAPTSMN1; SMN2 | |
| SCHEMBL11087705 | 0.71 | KDM4E (0.49) | TSHRKMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL1491206 | 0.71 | KMT2A (0.64) | KMT2AHTTMEN1MAPTSMN1; SMN2 | |
| SCHEMBL20141848 | 0.69 | EED (0.40) | TSHRKMT2AMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | TSHR 271/4885KMT2A 1330/4885HTT 497/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | TSHR 271/4885KMT2A 1330/4885HTT 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.